On May 29, 2019 OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, reported that Chief Executive Officer William Annett will present a company overview at the 2019 BIO International Convention, which is being held June 3 – 6, 2019 at the Pennsylvania Convention Center in Philadelphia (Press release, BioTime, MAY 29, 2019, View Source;p=RssLanding&cat=news&id=2400014 [SID1234536676]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Date: Wednesday, June 5
Time: 10:45am EDT
Location: Theatre 2
A live webcast of the presentation can be access using the following link: http://www.veracast.com/webcasts/bio/internationalconvention2019/81201224287.cfm
A replay of the webcast will be available through September 3, 2019.
About the BIO International Convention
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
The Convention allows for public and private companies to provide company presentations, request meetings with biotech investors and executives, attend educational sessions and engage in networking opportunities.
For more information, please visit: View Source
About DetermaVu
DetermaVu is being developed as an intermediate step to confirm the absence of cancer between imaging modalities (LDCTs) detecting suspicious lung nodules and downstream invasive procedures that determine if the nodules are malignant. OncoCyte estimates that a $2 billion to $4.7 billion annual market could develop in the U.S. for its confirmatory lung cancer liquid biopsy test, depending on the scope of physician utilization, market penetration and reimbursable pricing.
DetermaVu has the potential to dramatically reduce U.S. healthcare costs by billions of dollars each year by eliminating unnecessary biopsies, which, according to a study of Medicare data by an independent health economics firm, cost on average $14,634 each. In addition, DetermaVu can provide great benefit to patients by avoiding invasive biopsies and the complications that arise in up to 24% of those procedures, and deaths that occur in up to 1% of cases.
DetermaVu is a trademark of OncoCyte Corporation